REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Financière de Tubize – Dividend approval - April 26, 2025
- SWKS IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Skyworks Solutions, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 5 Deadline in Securities Class Action – SWKS - April 25, 2025
- Trillion Energy Announces Election to Issue Common Shares in Satisfaction of Convertible Debenture Interest Payment Obligations and Shares for Debt Settlement - April 25, 2025
